Dr. David Samadi Helps People Find a New Way to Look After Their Health

It’s no secret that it takes a long time to become a doctor. People seldom consider just how much knowledge is earned during that period. And once a medical doctor begins practicing he’ll continue to learn and innovate. This means that doctors have a wealth of knowledge that the average person lacks.

While people seldom notice that difference in knowledge, doctors know how much of a problem it can be. That’s why some of the leading figures in the medical industry are working hard to promote better understanding of health and medicine. The bigger the name the more significant the news. That’s why the news that Dr. David Samadi has found a new way to educate the public is so exciting.

Dr. David Samadi is hosting a new show called Sunday Housecall. The show is intended to help people get a better idea of what’s involved with modern medicine. The basic foundation of the show involves Dr. David Samadi teaching the audience about various medical topics. But the key defining point of the show is that it’s primarily an interactive process. The audience is always able to reach out and ask questions. Likewise other viewers will be able to benefit from those answers as well. If one person has a question it’s fairly safe to assume that others will too. This discussion format acts as a perfect way to educate the public on some very complex subjects.

Dr. David Samadi also brings in experts within various fields to get their take on the latest news from the medical world. This two tiered method of discussing medicine offers quite a few advantages for viewers. Dr. Samadi is able to act as quality control for the flow of information. He’s a fantastic public speaker who also possesses expertise in the field. As such, he can make sure that any guests live up to those standards as well. In doing so the audience has the advantage of always hearing from the experts in any given field of medicine.

Of course all of that hinges on the expertise of Dr. David Samadi himself. The doctor was offered the position for good reason. He’s a practicing physician, operating out of Lenox Hill Hospital. In that position he’s responsible for a wide range of duties. This extends all the way up to overseeing the robotics surgery program. The continuing integration of robots within medical care is about as cutting edge as medicine gets, and learn more about Dr. Samadi.

Part of what made Dr. Samadi so successful within the field is an understanding of how various schools of medicine can work together. For example, he quickly integrated his work with robotics into standard patient care. Doing so streamlines the surgical process while also providing real world feedback for the devices. This ability to push technologies and techniques into different fields is part of what makes him such a good host. He understands exactly how to take information from the medical world and translate it into something the public can understand, and http://reporterexpert.com/weekly-medical-insight-dr-david-samadi/.

Oncotarget and their aim at life without disease

Oncotarget is a weekly medical journal that is published twice weekly. Specializing in oncology the journal has been open-access to enable more people to make use of it. A publication of Impact Journals, Oncotarget was launched in 2010 and has Mikhail Blagosklonny and Andrei V. Gudkov of Roswell Park Cancer Institute as the chief editors. Operating under Creative Commons 3.0 License, the journal has been rated to have had an impact factor of 5.16 in the year 2016.The journal’s administrators announced on the journal’s official website that due to increased demand and circulation that the journal would get published twice weekly – Tuesdays and Fridays.

The auditors attribute the rising impact factor of the journal to insightful, constructive multiple peer-review articles that have enabled the contributing researchers to improve the impact size of their research. Oncotarget is ranked top among oncology journals by Scimago Journal and Country Rank (SJR) The ranking, which compared 50 publications, showed Oncotarget leading with over 6300 documents published in 2016 followed by followed by Oncology Letters with 2545 documents. Molecular Medicine Reports ranks third with 1475 papers while Asian Pacific Journal of Cancer Prevention comes fourth with 1068 papers. The ranking also considers other aspects such as the total number of times the articles in the journal have been cited by other authors and even the average number every document has been mentioned.

Oncotarget publishers say that their mission is ‘to make scientific results rapidly and widely available’ and to attain maximum impact levels of research by the use of insightful peer-reviews. The website also describes the journal as free-access, multidisciplinary and traditional in approach. The publication is released online, but the editors say that hard copies can get produced on demand. By this, they hope to facilitate quick sharing of remarkable discoveries. The journal further expects to create a link between biomedical fields and eliminate the divide between various boundaries. Also, the publication hopes to champion the application of fundamental and advanced scientific interventions to alleviate disease and promote health.Being under the leadership of senior scientists the publication aims at attaining life devoid of disease.

Dr. Mikhail Blagosklonny: Revolutionary Aging Doctor

Dr. Mikhail Blagoskloony is a scientist who studies aging and cancer. He earned his M.D in internal medicine and his PhD in external medicine from the First Pavlov State Medical University of St. Petersburg. In 2002, he was appointed associate professor of medicine at New Your Medical College. Shortly thereafter he accepted a position as senior scientist at Ordway Research Institute. Since 2009 Dr. Mikhail Blagoskloony is working as a professor of Oncology at Roswell Park Cancer Institute in New York. View his LinkedIn profile

Dr. Blagoskloony formulated a hypothesis about the possible role of TOR (Target of rapamycin) signaling in aging and cancer by the use of rapamcyin, a cancer drug as a possible treatment for life extension. In on words, it would be an anti-aging drug that would slow or reverse aging. While Dr. Blagoskloony was working on cancer patients, he realized that the same qualities that made rapamycin effective at slowing tumor growth, would possibly slow aging as well. In fact the doctor even takes rapamcyin himself.

His role as professor of Oncology at Roswell Park Cancer Institute in New York is to help facilitate the development of new anti-cancer strategies and development and methods of cancer protection that are not limited to: therapy, selective combination anticancer drugs, and prevention of cancer by slowing down organismal aging. of In addition to Mikhail Blagoskloony’s groundbreaking work in his field he is Founding Editor and Editor-in-Chief for Cell Cycle and Associate Editor of the following publications: PLOS ONE, Cancer Biology & Therapy, American Journal of Pathology, Cell Death & Differentiation, Autophagy, Cancer Research, and International Journal of Cancer. Follow Mikhail on Loop


The Success of Clay Siegall

Clay Siegall is an innovator and a businessman who was tested and found a new way to treat not only the many harmful and deadly cancerous side effects, but also how to treat cancer itself without ever having to use harmful radiation or chemicals in the process of eliminating the cancer cells. Clay Siegall is the founder of Seattle Genetics that was founded in 1998 to offer individuals with cancerous cells in all stages a new and cheaper alternative to the treatment. Clay Siegall has proved himself to be a top leader and innovator of the company who has involved himself with all of the discoveries of the company and is the force behind the innovation that is shown through this company and the results that this company provides to the customers. Mr. Siegall has demonstrated his capability with the product and has secured almost $700 million in private as well as public investments.

Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors

In recent news, Clay Siegall was honored with a new position to be appointed to the board of directors for Mirna Therapeutics as he has shown his excellence within the business industry in addition to his excellence that has been shown in the industry of biotechnology. Dr. Siegall will be a distinguished member of the group and will act as a mentor to the board. Dr. Siegall will continue his innovative progress and will help develop Mirna Therapeutics in both the science aspect of the company as well as in the business side of the company.

Mirna is a company that, like Seattle Genetics, specializes in biotechnology and ingenuity. With some of the top experts in the oncology department involved with the creation of a great product to help with the body, Mirna is truly and innovative company that will prove to help the lives of many individuals on the way to success. The goal of these biotechnology companies is to target to cancerous cells directly without harming the good cells within the body. This means no side effects will be involved with the treatment that are often associated with radiation as well as with chemotherapy.



Dr. Clay Siegall Leads the Way

Seattle Genetics is making great strides towards becoming one of the top oncology multi-product companies worldwide. They have many clinical trials currently underway and are showing great promise with upcoming trials being planned for the near future. The financial outlook for the company is strong with net sales continuing to rise.

Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript

Seattle Genetics base their company around the biotechnology principle of using organisms and cells for product development. Their goal is to help patients that have been diagnosed with cancer live longer healthier lives. They use antibody-drug conjugates, or ADCs, to target cancer cells. This has proven to be effective for both cancer and autoimmune diseases.

Leading the Way

Clay Siegall is the Chief Executive Officer, Chairman of the Board, and President of Seattle Genetics. He has been the guiding force behind raising the capital that was needed to move the company forward. Dr. Siegall received a Bachelor of Science degree in Zoology from the University of Maryland and a Ph.D. in Genetics at George Washington University. His work experience has paved a path to where he is today including Bristol-Myers Squibb Pharmaceutical Research Institute, National Cancer Institute, National Institute of Health, and has served on several boards.

Awards and Accolades

Clay B. Siegall accomplishments can be seen in the number of awards he has received such as the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year and the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. He is the holder of over 15 patents and is an accomplished writer having been published in over 70 publications.

Helping Others

Dr. Siegall’s passion to help others was the driving force he needed to help found Seattle Genetics. He encourages innovation, research, and drug development practices within the company. Seattle Genetics is continuing to grow by expanding their product lines. People all over the world are now able to benefit from the hard work and dedication of Dr. Siegall and his associates. Giving people hope for the future is something that Seattle Genetics and Clay Siegall are striving to accomplish.



Seattle Genetics a Leader in Scientific Innovation

Seattle Genetics is perhaps one of the lesser known innovators in the scientific world. Under the leadership of Clay Siegall, the company has grown to be a lot more than just a whisper in the wind. Siegall founded Seattle Genetics in 1998. Siegall is a trained scientist and specialized in cancer research. When he founded Seattle genetics, he wanted them to be a leader in innovation as well as research that was described as rigorous and overall a sense of wanting to help others to live a better and more productive life.

Siegall and his team help to develop antibody drug conjugates. This development helped later on to lead to the 2011 approval of their first ADC product named ADCETRIS. It has went on to become approved in more than 60 countries and has helped to put Siegall and Seattle Genetics in the public eye. With his leadership, Seattle Genetics has been able to partner with a number of manufacturers including Genentech, GlaxoSmithCline as well as Pfizer and have generated more than 300 million to date.

Using Seattle Genetics technology through a series of collaborations there are more than 20 ADC’s currently in development. Siegall has also been responsible for a large amount of capital fund raising totaling around 1.2 billion that was secured through a series of public and private fund raising. Before founding Seattle genetics, Clay Siegal was active with a number of companies, in the medical industry. Before he started his career, Siegal received a Ph.D in genetics from George Washington University and a degree in zoology from the University of Maryland.

With Clay Siegall’s leadership and the technological advances that Seattle Genetics are making, it is easy to see how this will lead to there being a lot of advances in the coming years that will hopefully help to conquer a number of the diseases that have been plaguing us all these years.

Seattle Genetics: Leading the Way in Antibody-Drug Conjugates

Seattle Genetics is a biotech company on a mission to provide the world with the finest antibody-based therapies for cancer treatment. Their research focuses on using monoclonal antibodies to target cancer cells while avoiding doing damage to other cells within the body. The kinds of drugs they work on are called antibody-drug conjugates, or ADCs for short. They hope that their drugs will be able to save many patients from having to undergo often hazardous chemotherapy procedures in the future.

The best known drug put out by Seattle Genetics is called ADCETRIS. This cancer-fighting drug is currently available in over 60 countries. The team at Seattle Genetics hopes they can strengthen this drug with further research to treat different kinds of lymphoma in the near future.

Currently Clay Siegall is the CEO and President of Seattle Genetics. Dr. Siegall also co-founded this company back in 1998.

Dr. Siegall earned his B. S. in Zoology from the University of Maryland. After that, he was awarded his Ph.D. in Genetics at George Washington University.

After graduating from college, Dr. Siegall worked for many prestigious institutions. Dr. Siegall worked at both Bristol-Myers’ Squibb Pharmaceutical Research Institute and the National Cancer Institute before forming Seattle Genetics. In addition to his post as the head of Seattle Genetics, Dr. Siegall is on the Boards of Directors of many other companies, including Ultragenyx Pharmaceutical, Mirna Therapeutics, and Alder BioPharmaceuticals.

In creating Seattle Genetics, Dr. Siegall wished to create a company that had a rigorous work ethic, an encouraging atmosphere for innovation, and a clear awareness of the patients they are serving. Thus far, Dr. Siegall has led his company towards many lucrative alliances with major players in the pharma world, including Pfizer, AbbVie, and GlaxoSmithKline.

For all of his work in both research and development of ADCs, Dr. Siegall has been given many awards in recent years. Dr. Siegall was recently given an alumni award from his alma mater the University of Maryland. Dr. Siegall also recognized as the Pacific Northwest Ernst & Young Entrepreneur of 2012.

Learn More